These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 21621343)

  • 1. Long-term quality of life outcome after proton beam monotherapy for localized prostate cancer.
    Coen JJ; Paly JJ; Niemierko A; Weyman E; Rodrigues A; Shipley WU; Zietman AL; Talcott JA
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e201-9. PubMed ID: 21621343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life.
    Morton GC; Loblaw DA; Sankreacha R; Deabreu A; Zhang L; Mamedov A; Cheung P; Keller B; Danjoux C; Szumacher E; Thomas G
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):811-7. PubMed ID: 19836166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of long-term quality of life and voiding function of patients treated with radical prostatectomy or permanent brachytherapy for prostate cancer.
    Bradley EB; Bissonette EA; Theodorescu D
    BJU Int; 2004 Nov; 94(7):1003-9. PubMed ID: 15541117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective assessment of patient-reported long-term urinary morbidity and associated quality of life changes after 125I prostate brachytherapy.
    Stone NN; Stock RG
    Brachytherapy; 2003; 2(1):32-9. PubMed ID: 15062161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life impact of treatments for localized prostate cancer: cohort study with a 5 year follow-up.
    Ferrer M; Guedea F; Suárez JF; de Paula B; Macías V; Mariño A; Hervás A; Herruzo I; Ortiz MJ; Ponce de León J; Sancho G; Boladeras A; Ayala A; Craven-Bratle J; Ávila M; Cunillera O; Pardo Y; Alonso J; Aguiló F;
    Radiother Oncol; 2013 Aug; 108(2):306-13. PubMed ID: 23849168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 3-y prospective study of health-related and disease-specific quality of life in patients with nonmetastatic prostate cancer treated with radical prostatectomy or external beam radiotherapy.
    Yoshimura K; Arai Y; Ichioka K; Matsui Y; Ogura K; Terai A
    Prostate Cancer Prostatic Dis; 2004; 7(2):144-51. PubMed ID: 15111981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adding intensity-modulated radiotherapy to the pelvis does not worsen the adverse effect profiles compared to limited field radiotherapy in men with prostate cancer at 12-month follow-up.
    Lilleby W; Stensvold A; Dahl AA
    Acta Oncol; 2014 Oct; 53(10):1380-9. PubMed ID: 24844918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy.
    Miller DC; Sanda MG; Dunn RL; Montie JE; Pimentel H; Sandler HM; McLaughlin WP; Wei JT
    J Clin Oncol; 2005 Apr; 23(12):2772-80. PubMed ID: 15837992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function.
    Chen RC; Clark JA; Talcott JA
    J Clin Oncol; 2009 Aug; 27(24):3916-22. PubMed ID: 19620493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer.
    Ferrer M; Suárez JF; Guedea F; Fernández P; Macías V; Mariño A; Hervas A; Herruzo I; Ortiz MJ; Villavicencio H; Craven-Bratle J; Garin O; Aguiló F;
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):421-32. PubMed ID: 18325680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radical prostatectomy versus high-dose rate brachytherapy for prostate cancer: effects on health-related quality of life.
    Jo Y; Junichi H; Tomohiro F; Yoshinari I; Masato F
    BJU Int; 2005 Jul; 96(1):43-7. PubMed ID: 15963118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rectal dose-volume histogram parameters are associated with long-term patient-reported gastrointestinal quality of life after conventional and high-dose radiation for prostate cancer: a subgroup analysis of a randomized trial.
    Nguyen PL; Chen RC; Hoffman KE; Trofimov A; Efstathiou JA; Coen JJ; Shipley WU; Zietman AL; Talcott JA
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1081-5. PubMed ID: 20207497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer.
    Frank SJ; Pisters LL; Davis J; Lee AK; Bassett R; Kuban DA
    J Urol; 2007 Jun; 177(6):2151-6; discussion 2156. PubMed ID: 17509305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-reported quality of life during radiation treatment for localized prostate cancer: results from a prospective phase II trial.
    Chen RC; Zhang Y; Chen MH; McMahon E; Loffredo M; McPherson CP; Nguyen AU; Nguyen PL; D'Amico AV
    BJU Int; 2012 Dec; 110(11):1690-5. PubMed ID: 22502770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-related quality of life and treatment outcomes for men with prostate cancer treated by combined external-beam radiotherapy and hormone therapy.
    Hashine K; Azuma K; Koizumi T; Sumiyoshi Y
    Int J Clin Oncol; 2005 Feb; 10(1):45-50. PubMed ID: 15729601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expanded Prostate Cancer Index Composite versus Incontinence Symptom Index and Sexual Health Inventory for Men to measure functional outcomes after prostatectomy.
    Hedgepeth RC; Labo J; Zhang L; Wood DP
    J Urol; 2009 Jul; 182(1):221-7; discussion 227-8. PubMed ID: 19450842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study.
    Potosky AL; Davis WW; Hoffman RM; Stanford JL; Stephenson RA; Penson DF; Harlan LC
    J Natl Cancer Inst; 2004 Sep; 96(18):1358-67. PubMed ID: 15367568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute and late toxicity after dose escalation to 82 GyE using conformal proton radiation for localized prostate cancer: initial report of American College of Radiology Phase II study 03-12.
    Coen JJ; Bae K; Zietman AL; Patel B; Shipley WU; Slater JD; Rossi CJ
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1005-9. PubMed ID: 20932675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer.
    Gore JL; Kwan L; Lee SP; Reiter RE; Litwin MS
    J Natl Cancer Inst; 2009 Jun; 101(12):888-92. PubMed ID: 19509365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-related quality of life in patients with locally advanced prostate cancer after 76 Gy intensity-modulated radiotherapy vs. 70 Gy conformal radiotherapy in a prospective and longitudinal study.
    Lips I; Dehnad H; Kruger AB; van Moorselaar J; van der Heide U; Battermann J; van Vulpen M
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):656-61. PubMed ID: 17512127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.